Comparison of Risperidone and Methylphenidate for Reducing ADHD Symptoms in Children and Adolescents With Moderate Mental Retardation - 21/08/11
ABSTRACT |
Objective |
To evaluate the short-term efficacy and tolerability of risperidone and methylphenidate for reducing symptoms related to attention-deficit/hyperactivity disorder (ADHD) in children and adolescents with moderate mental retardation.
Method |
In a 4-week, single-blind, parallel-group trial, 45 subjects with moderate mental retardation and ADHD were randomized to risperidone or methylphenidate and assessed using objective rating scales for efficacy (SNAP [Swanson, Nolan, and Pelham]-IV and Nisonger Child Behavior Rating Form) and side effects (Barkley’s Side Effects Rating Scale and Udvalg for Kliniske Undersøgelser).
Results |
Both groups had reduced ADHD symptoms during the trial. Repeated-measures analysis of variance yielded a significant effect for the interaction between time and group assignment in SNAP-IV Total scores (F = 3.26; p = .05), suggesting a more pronounced effect for risperidone. There was a significant weight reduction in the methylphenidate group and a weight gain in the risperidone group.
Conclusions |
Our findings suggest that risperidone is associated with greater reductions in ADHD Total score than methylphenidate in children with moderate mental retardation and ADHD. Comorbidity and the side effects profile might be of importance in choosing between the medications, although it is usually prudent to try stimulants before antipsychotics in such children.
Le texte complet de cet article est disponible en PDF.Key Words : attention-deficit/hyperactivity disorder, mental retardation, methylphenidate, risperidone
Plan
| This work was partially supported by research grants from Hospital de Clínicas de Porto Alegre, FAPERGS, NOVARTIS, and JANSSEN-CILAG. Disclosure: The ADHD outpatient program receives research support from the following pharmaceutical companies: Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, and Novartis. Dr. Rohde is on the speaker’s bureau or is a consultant for the same companies. Dr. Aman is on Janssen Pharmaceutica’s U.S. Pediatric Advisory Board and has a research contract from Janssen. The other authors have no financial relationships to disclose. |
Vol 44 - N° 8
P. 748-755 - août 2005 Retour au numéro
- Childhood Predictors of Psychiatric Disorders Among Boys: A Prospective Community-Based Follow-up Study From Age 8 Years to Early Adulthood
- Andre Sourander, Petteri Multimäki, Georgios Nikolakaros, Antti Haavisto, Terja Ristkari, Hans Helenius, Kai Parkkola, Jorma Piha, Tuula Tamminen, Irma Moilanen, Kirsti Kumpulainen, Fredrik Almqvist
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?